Senti Biosciences, Inc. (SNTI) Investor Relations Documents

Senti Biosciences, Inc. (SNTI) investor relations documents from the company's IR site: 1 presentation, 23 press releases. Read in-app with summaries. First-party data.

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Ann: Senti Bio will present three preclinical studies at the 2023 AACR Annual Meeting, highlighting its gene circuit-enhanced CAR-NK cell therapy pipeline.

Investor relations documents — source: company IR site

Published	Type	Document
2026-07-15	Press release	Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline
2026-05-14	Press release	Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program
2026-05-14	Press release	Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202
2026-04-13	Press release	Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
2026-04-01	Press release	Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
2026-03-27	Press release	Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
2026-03-23	Press release	Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
2026-03-03	Press release	Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
2026-02-24	Press release	Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
2026-02-20	Press release	Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Devel
	Press release	Senti Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
	Press release	Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
	Press release	Senti Bio Reports Second Quarter Financial Results and Business Updates
	Press release	Senti Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
	Press release	Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Associa
	Presentation	Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Ann
	Press release	Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
	Press release	Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
	Press release	Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
	Press release	Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
	Press release	Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
	Press release	Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
	Press release	Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
	Press release	Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

SNTI overview · SNTI earnings · SNTI financials · SNTI KPIs · SNTI ownership · SNTI peers · SNTI filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.